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ABSTRACT
Background Obstructive sleep apnoea (OSA) is 
associated with higher body mass index (BMI), diabetes, 
older age and male gender, which are all risk factors for 
severe COVID-19.
We aimed to study if OSA is an independent risk factor for 
COVID-19 infection or for severe COVID-19.
Methods OSA diagnosis and COVID-19 infection 
were extracted from the hospital discharge, causes of 
death and infectious diseases registries in individuals 
who participated in the FinnGen study (n=260 405). 
Severe COVID-19 was defined as COVID-19 requiring 
hospitalisation. Multivariate logistic regression model 
was used to examine association. Comorbidities for 
either COVID-19 or OSA were selected as covariates. We 
performed a meta- analysis with previous studies.
Results We identified 445 individuals with COVID-19, 
and 38 (8.5%) of them with OSA of whom 19 out of 
91 (20.9%) were hospitalised. OSA associated with 
COVID-19 hospitalisation independent from age, sex, 
BMI and comorbidities (p- unadjusted=5.13×10−5, OR- 
adjusted=2.93 (95% CI 1.02 to 8.39), p- adjusted=0.045). 
OSA was not associated with the risk of contracting 
COVID-19 (p=0.25). A meta- analysis of OSA and severe 
COVID-19 showed association across 15 835 COVID-19 
positive controls, and n=1294 patients with OSA with 
severe COVID-19 (OR=2.37 (95% 1.14 to 4.95), p=0.021).
Conclusion Risk for contracting COVID-19 was the same 
for patients with OSA and those without OSA. In contrast, 
among COVID-19 positive patients, OSA was associated 
with higher risk for hospitalisation. Our findings are in line 
with earlier works and suggest OSA as an independent risk 
factor for severe COVID-19.
INTRODUCTION
COVID-19 is a severe respiratory disease 
caused by SARS- CoV-2 virus infection. A 
subset of patients face hospitalisation, respira-
tory failure or even death. The severity of 
COVID-19 is highly age dependent but also 
evidenced by the number of individuals that 
receive hospital and intensive care treat-
ment.1 2 Finland has had a relatively small 
number of COVID-19 cases in the spring 
of 2020. However, approximately 1%–6% 
of those tested positive for the virus in 
Finland received hospital or intensive care 
treatment.3 These percentages are similar to 
those reported globally.1 2 Severe COVID-19 
outcome is mediated primarily through 
respiratory distress.4 5 Risk factors for severe 
COVID-19 have been identified as older age, 
male sex, obesity, diabetes, cardiovascular 
disease and poor lung function.6 In addi-
tion, other respiratory diseases have been 
listed as potential contributors for COVID-19 
severity. Indeed, there are studies suggesting 
that obstructive sleep apnoea (OSA) may be 
a risk factor for severe COVID-19.7–12 Such 
risk would have substantial effect as OSA is a 
common disease affecting at least 8% of the 
population with higher prevalence in older 
age groups reaching to over 20% in individ-
uals over 60 years of age.13 The disease aeti-
ology of OSA is characterised by repetitive 
apnoea- hypopnea cycles during sleep causing 
shortness of breath which can be associated 
with sometime severe oxygen desaturation, 
sleep disruption and increase in systolic and 
diastolic blood pressure.14 The known risk 
factors for OSA include obesity, high age, 
male sex and craniofacial and upper airway 
structure variations and anomalies.15 Simi-
larly, OSA is associated with increased risk 
for cardiovascular mortality, especially if not 
treated. Finally, it is essential to note that 
treatment exists for the majority of patients 
with OSA so that night- time breathing can be 
Key messages
 ► Is obstructive sleep apnoea (OSA) an independent 
risk factor for severe COVID-19?
 ► Patients with OSA have a higher risk to be hospi-
talised when affected by COVID-19 than non- OSA 
individuals.
 ► In assessment of patients with suspected or con-
firmed COVID-19 infection, OSA should be rec-
ognised as one of the comorbidity risk factors for 
developing a severe form of the disease and patients 
with OSA with suspected or confirmed COVID-19 in-
fection should be monitored closely.
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supported by continuous positive airway pressure (CPAP) 
or mandibular advancement device (MAD). This treat-
ment substantially decreases the risk for cardiovascular 
events and death.16 17 Recently, questions have been 
raised about whether OSA constitutes a high risk for 
COVID-19 infection or COVID-19 hospitalisation.
We specifically aimed at evaluating if OSA associ-
ates with the risk for severe COVID-19 infection inde-
pendently of other potential risk factors including age, 
sex, body mass index (BMI), hypertension, diabetes 
(including type 1 and type 2 diabetes), coronary heart 
disease (CHD) asthma and chronic obstructive pulmo-
nary disease (COPD), and also whether the risk for 




FinnGen (https://www. finngen. fi/ en) is a large biobank 
study that aims to genotype 500 000 Finns including 
two types of biobank collections: (1) population- based 
epidemiological cohorts and (2) mostly disease- based 
collections in all University Hospitals in Finland (online 
supplemental table 1). FinnGen combines these data with 
longitudinal registry data that record healthcare events 
over the entire lifespan including the National Hospital 
Discharge Registry (available from 1968), the Causes 
of Death Registry (available from 1969), the National 
Infectious Diseases Registry (available from 1995) and 
the Medication Reimbursement Registry (available from 
1995), all these using unique national personal identifi-
cation codes, for the whole population of Finland for life-
time information since the start of each registry. FinnGen 
has harmonised data from these registries of 260 405 
Finnish individuals. Registry data were available from 
the beginning of the registry until 31 December 2018 
and Infectious Registry data until 30 October 2020. In 
addition, demographic and anthropometric data of BMI 
and smoking status are included.
The information of COVID-19 positive individuals was 
collected from The National Infectious Diseases Registry 
and the infection was verified by laboratory test using 
PCR testing. Data for risk factors, comorbidities and 
OSA diagnosis were obtained from the National Hospital 
Discharge Registry, the Causes of Death Registry and the 
Medication Reimbursement Registry, where the clin-
ical endpoints had been generated using International 
Classification of Diseases codes for OSA, hypertension, 
diabetes (including type 1 and type 2 diabetes), CHD, 
asthma and COPD (online supplemental table 2).
Treatment information concerning OSA was collected 
from the patient records of Heart and Lung Center or 
Department of Oral and Maxillofacial Diseases, Helsinki 
University Hospital (HUH), Finland.
The diagnosis in this special healthcare derived data for 
OSA is typically based on the following criteria: subjective 
symptoms, clinical examination and sleep registration 
applying Apnoea- Hypopnea Index (AHI) 5≥per hour for 
polysomnography or respiratory event index 5≥per hour 
for out- of- centre sleep study.
For the meta- analysis, estimates were collected from 
the previous studies7–9 concerning the role of OSA on 
COVID-19 hospitalisation.
Statistical methods
Differences in baseline demographics and clinical char-
acteristics were tested using on χ2 tests. Fisher’s exact 
test was used if the expected cell size was ≤5. For contin-
uous variables, Student’s t- test was used. We considered 
p<0.05 as statistically significant, and all tests were two 
sided (tables 1 and 2). All p values based on foremen-
tioned tests are Bonferroni corrected. Logistic regression 
was used to calculate OR between hospitalised and non- 
hospitalised groups. Model 1 was adjusted for age and 
Table 1 Comparison of the baseline characteristics among COVID-19 positive individuals
  
All
n=445 Non- hospitalised n=354
Hospitalised
n=91 Punadjusted
Age (mean in years, SD) 52.7 (17.4) 49.3 (16.3) 65.9 (14.8) 1.06×10−15*
Sex (male) (N, %) 166 (37.3) 133 (37.6) 33 (36.3) 1
OSA (N, %) 38 (8.5) 19 (5.4) 19 (20.9) 5.13×10−5*
BMI (mean kg/m2, SD) 27.13 (5.44) 26.54 (5.20) 29.25 (5.78) 0.014*
Hypertension (N, %) 79 (17.8) 40 (11.3) 39 (42.9) 5.03×10−11*
Diabetes (N, %) 46 (10.3) 23 (6.5) 23 (25.3) 3.45×10−6*
CHD (N, %) 21 (4.7) 9 (2.5) 12 (13.2) 5.20×10−4*
Asthma/COPD 54 (12.1) 40 (11.3) 14 (15.4) 1
Differences and associations between non- hospitalised and hospitalised COVID-19 positive individuals. Baseline demographics and 
clinical characteristics Punadjusted values were based on χ
2 test. For continuous variables, we used Student’s t- test. BMI was measured of 264 
participants including 206 non- hospitalised and 58 hospitalised individuals.
*Statistically significant.
BMI, body mass index; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; OSA, obstructive sleep apnoea.
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sex. Model 2 was adjusted for BMI in addition to covar-
iates of Model 1. Model 3 was adjusted for BMI, hyper-
tension, diabetes, CHD, asthma and COPD in addition 
to covariates of Model 1 (table 3) and similarly between 
COVID-19 -positive and non- COVID-19 groups .
Our results and previous findings from the corre-
sponding studies7–9 were pooled together forming a 
meta- analysis using restricted maximum likelihood esti-
mation of the random effect model in the Metagen R. 
The merged data consisted of 15 835 COVID-19 positive 
individuals including 1294 patients with OSA.
The R statistical package (V.4.0.2) was used for all anal-
yses ( www. r- project. org)
Patient and public involvement
Patients and public were not involved in the designing 
process of this study. The patients will not be informed 
individually of the study results otherwise than through 
possible media coverage.
RESULTS
The data included 260 405 Finnish individuals from 
FinnGen Data Freeze 6 with 445 patients with COVID-19. 
Of them, 38 (8.5%) had OSA. Severe COVID-19 cases 
(n=91) included 19 (20.9%) patients with OSA. Severe 
COVID-19 was defined as an infection requiring hospi-
talisation.
Of all patients with COVID-19 diagnosis (n=445, 37.3% 
male, mean age 52.7 years) 38 patients also had OSA 
diagnosis (8.5%, 50.0% male, mean age 61.3 years), 
(tables 1 and 2). This reflects a similar prevalence of OSA 
diagnoses in COVID-19 infected as in the normal popu-
lation in FinnGen, where prevalence is 8%.18 Ninety- one 
(20.4%) patients required hospitalisation (36.3% male, 
mean age 65.9 years) including 19 patients with OSA 
(table 1).
Prevalence of OSA (p=5.13×10−5), hypertension 
(p=5.03×10−11), diabetes (p=3.45×10−6) and CHD 
(p=5.20×10−4) were statistically significantly higher in the 
hospitalised group. Similarly, age and BMI were higher 
among hospitalised individuals (p=1.06×10-15, p=0.014, 
respectively; table 1).
To evaluate the performance of the diagnostic events, 
we compared the main risk factors among patients with 
COVID-19 between individuals with OSA (n=38) and 
those who did not have OSA diagnosis (n=407). Patients 
with OSA were statistically significantly older and their 
BMI was higher (mean age 61.3 years, BMI 31.15 kg/m2, 
p=5.60×10−4, p=3.38×10−3, respectively) than non- OSA 
individuals (mean age 51.9 years, BMI 26.71 kg/m2). 
Also, comorbidities were more prevalent among OSA 
individuals (p=1.74×10−4) and they faced hospitalisation 
more often (p=3.21×10−5). We did not observe differ-
ences in risk factors when comparing non- hospitalised 
(n=19, male 63.2%, mean age 56.3 years) and hospital-
ised patients with OSA (n=19, male 36.8%, mean age 
66.3 years; table 2). Furthermore, 7/19 patients with 
OSA were hospitalised due to COVID-19 did not have 
any other disease comorbidities. We did not observe 
significant differences concerning age or BMI between 
individuals who had only OSA as a comorbidity or also 
Table 2 Description of patients with COVID-19 with or without obstructive sleep apnoea (OSA) and a comparison between 












Age (mean in years, SD) 51.9 (17.5) 61.3 (12.9) 5.60×10−4* 56.3 (11.0) 66.3 (12.9) 0.057
Sex (male) (N, %) 147 (36.1) 19 (50.0) 0.645 12 (63.2) 7 (36.8) 0.776
BMI (mean kg/m2, SD) 26.71 (5.27) 31.15 (5.56) 3.38×10−3* 30.91 (5.58) 31.37 (5.77) 1
Comorbidities or outcomes 
(N, %)
118 (29.0) 24 (63.2) 1.74×10−4* 12 (63.2) 12 (63.2) 1
Hospitalised (N, %) 72 (17.7) 19 (50.0) 3.21×10−5*
Differences between non- OSA versus OSA individuals and non- hospitalised patients with OSA versus hospitalised patients with OSA among 
COVID-19- positive individuals. 7/19 patients with hospitalisation had OSA diagnosis but did not have any other disease comorbidities P 
values were based on χ2 test. Fisher’s exact test was used if the sample size was ≤5. For continuous variables, we used Student’s t- test. BMI 
was measured of 264 participants including 239 non- OSA and 25 OSA individuals. Comorbidities and outcomes=hypertension, diabetes, 
coronary heart disease, asthma, chronic obstructive pulmonary disease.
*Statistically significant.
BMI, body mass index.
Table 3 ORs associating obstructive sleep apnoea with 
severe COVID-19
OR 95% CI P value
Model 1 3.85 1.82 to 8.13 4.13×10−4*
Model 2 3.45 1.27 to 9.35 0.016*
Model 3 2.93 1.02 to 8.39 0.045*
Model 1 is adjusted for age and sex. Model 2 is adjusted for body 
mass index (BMI) in addition to covariates of Model 1. Model 3 is 
adjusted for BMI, hypertension, diabetes, coronary heart disease, 
asthma and chronic obstructive pulmonary disease in addition to 
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other comorbidities in addition to OSA (62.8 years, 68.9 
years, p=0.72, 30.26 kg/m2, 32.67 kg/m2, p=1.00, respec-
tively). Time since the first diagnosis of OSA to COVID-19 
infection was not significantly different between non- 
hospitalised and hospitalised groups (6.6 years, 8.6 years, 
p=0.37, respectively).
We tested if OSA is associated with the risk of severe 
COVID-19 infection, determined as being hospitalised 
(n=91), or COVID-19 infection in general (n=445). While 
OSA did not affect the risk of contracting COVID-19 
(p=0.25), patients with OSA had a considerably elevated 
risk for being hospitalised due to severe COVID-19 
(OR=2.93 (95% CI 1.02 to 8.39), p=0.045, adjusted for 
age, sex, BMI, hypertension, diabetes, CHD, asthma and 
COPD; table 3).
We performed a meta- analysis by pooling the compa-
rable endpoints between the published studies7–9 and 
examined the association with severe COVID-19 with and 
without adjusting for BMI. The studies, including our 
study, consisted of 15 835 COVID-19 positive individuals 
including 1294 patients with OSA. Overall, we observed 
over twofold increase in the pooled estimate prior to 
adjusting for BMI (OR=2.37 (1.14 to 4.95), p=0.021). 
Adjusted estimates were available in the study of Cade 
et al8 (BMI) and Maas et al9 (BMI, hypertension and 
diabetes) but not in the study of Cariou et al.7 The pooled 
estimate somewhat attenuated after adjustment for BMI 
(OR=1.55 (0.88 to 2.72), p=0.13; figure 1).
To investigate patients with OSA contracted with 
COVID-19 in more detail, we accessed the healthcare 
data of 305 COVID-19 positive individuals including 11 
patients with OSA treated in Heart and Lung Center or 
Department of Oral and Maxillofacial Diseases, HUH, 
Finland by the end of October 2020. The mean age of 
the COVID-19 positive patients with OSA was 55.1 years, 
mean BMI was 35.08 kg/m2 and 9 (81.8%) patients were 
male. Mean AHI was 43.3 events per hour (table 4) and all 
11 patients had either moderate (AHI≥15 but<30 events 
per hour) or severe (AHI≥30 events per hour) OSA; 9 
out of 11 had severe OSA and 2 out of 11 had moderate 
OSA. 8/11 had treated OSA; 7 patients had CPAP therapy 
and 1 patient had MAD. CPAP- treated patients used their 
appliances 98% of the nights with 6.3 hours mean time 
used. Mean AHI during treatment was 1.86 events/hour 
prior to the COVID-19 infection. Despite of the OSA 
treatment, all 11 patients required hospital treatment 
caused by pneumonia or other COVID-19 caused symp-
toms, such as high fewer. All patients needed non- invasive 
ventilation and two required intubation. Treatment time 
in hospital was 15 days (mean, table 4).
DISCUSSION
Here, we examined the role of OSA as a risk factor for 
COVID-19 leading to hospitalisation. Our analyses 
revealed 2.93- times higher risk for COVID-19 hospitali-
sation in patients with OSA, independently of BMI and 
other known risk factors for OSA, or those for severe 
Figure 1 Forest plots of obstructive sleep apnoea (OSA) 
and the risk of hospitalisation due to COVID-19 The 
evidence is combined using random- effect meta- analysis. 
The data consisted of 15 835 COVID-19 positive individuals 
including 1294 patients with OSA. (A) The model is adjusted 
for age and sex, and ethnic background if available. *Cariou 
et al study’s primary outcome was defined as tracheal 
intubation and/or death within 7 days of admission. (B) The 
model is adjusted for age, sex and BMI. **Maas et al study 
is adjusted for diabetes and hypertension in addition to 
forementioned covariates.
Table 4 Healthcare data characteristics of individuals with 
obstructive sleep apnoea contracted with COVID-19
n=11
Age (mean in years) 55.1 (8.0)
Sex (male) (N, %) 9 (81.8)
BMI (mean kg/m2, SD) 35.08 (5.96)
Diabetes (N, %) 3 (27.3)
Hypertension (N, %) 7 (63.6)
CHD (N, %) 3 (27.3)
CPAP (N, %) 7 (63.6)
MAD (N, %) 1 (9.1)
AHI (mean, events per hour) 43.3 (20.6)
ODI (mean, events per hour) 39.6 (15.7)
SpO2 mean (mean%, SD) 91.0 (3.3)
SpO2 min (mean%, SD) 79.4 (8.3)
AHI with CPAP (mean, events per hour) 1.86 (2.07)
ICU (N, %) 3 (27.3)
NIV (N, %) 11 (100)
Intubation (N, %) 2 (18.2)
Treatment time in hospital (mean in days, SD) 15 (8.6)
AHI, Apnoea- Hypopnea Index; BMI, body mass index; CHD, 
coronary heart disease; CPAP, continuous positive airway 
pressure; ICU, intensive care unit; MAD, mandibular advancement 
devise; NIV, non- invasive ventilation; ODI, oxygen desaturation 
index; SpO2, oxygen saturation.
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COVID-19 suggesting that OSA is an independent risk 
factor for COVID-19.
Indeed, our findings are well in line with earlier works 
on COVID-19 comorbidities and OSA. Three studies 
have examined the association between COVID-19 and 
OSA before. Despite different endpoint definitions 
(contracting COVID-19, severity of the disease, mechan-
ical ventilation, and death), these studies share similar 
findings with ours. All studies showed a significant associ-
ation with COVID-19 severity and OSA.7–9 However, only 
one study showed a statistically significant association 
between OSA and severe COVID-19 after adjusting for 
BMI.9 These findings suggest that while OSA is likely a 
risk factor for COVID-19, evaluating the magnitude of 
this association would benefit from harmonised analyses 
across different cohorts where comorbidities are similarly 
assessed.
Building on these studies, we set to test the role of OSA 
on COVID-19 hospitalisation. In our study, patients with 
OSA had 2.93 times higher risk of being hospitalised and 
the estimate was comparable and independent of the 
risk in diabetes patients, where elevated risk has been 
reported earlier for severe COVID-19.19 There are at least 
two potential pathological mechanisms how OSA may 
relate to severe COVID-19. First, individuals with OSA 
often have one or more comorbidities that are known 
risk factors for severe COVID-19. For example, high 
BMI increases the risk for severe COVID-19. Further-
more, OSA exacerbates the effects of many underlying 
risk factors increasing blood pressure. Second, OSA may 
worsen the core symptoms of severe COVID-19, espe-
cially during the night, when decreased oxygen satura-
tion levels occur in OSA.14 Our findings together with 
earlier reports suggest that OSA should be taken into 
account when assessing who will develop life- threatening 
complications of COVID-19 infection.
In addition, we collected treatment information 
concerning OSA of 11 patients who had contracted 
COVID-19. Despite of the OSA treatment, patients 
developed a severe form of COVID-19 and all patients 
required hospital care suggesting OSA as a risk factor 
even if treated.
Finally, based on our results and previous studies,7–9 
we set a meta- analysis to strengthen the role of OSA 
on COVID-19 hospitalisation. We were able to establish 
OSA as a risk factor and show that the effect is related to 
COVID-19 severity indicating over 2- fold risk.
Our findings should be interpreted in the context that 
registry- based ascertainment through hospitalisation 
may miss non- hospitalised OSA cases (false negatives). 
In addition, the population prevalence of OSA is larger 
than the observed prevalence as OSA is still underdiag-
nosed in Finland. This may affect to our findings. The 
high percentage of individuals in hospitals likely reflect 
the age distribution of the first wave patients in Finland, 
where infections took place in individuals approximately 
50 years of age, and selective testing in those that had 
clear or severe symptoms. Similarly, early on the testing 
was targeted towards older individuals and to those 
with comorbidities, as not enough testing capacity was 
available early in the spring 2020. Although sufficient 
capacity and different strategies are in place now, the 
number of patients with mild COVID-19 infection may 
have not been recorded in the registries from the early 
spring 2020. Finally, compared with other countries there 
have been relatively small numbers of COVID-19 infec-
tions in Finland till the end of October 2020 when these 
data were curated. Therefore, while the effect estimates 
are comparable to other studies on OSA and COVID-19, 
the confidence intervals are relatively large due to the 
smaller total number of COVID-19 positive individuals in 
Finland and in the study sample: less than 500 patients 
compared with several hundred in other studies. Also, 
FinnGen represents older population (mean 58.6 years) 
than the average age (mean 42.9 years) in Finland.20
In conclusion, patients with OSA have the same risk of 
contracting COVID-19 than non- OSA individuals. Mean-
while, in this study, patients with OSA had 2.93 times 
higher risk to be hospitalised when affected by COVID-19 
than non- OSA individuals. Our findings may suggest that, 
in assessment of patients with suspected or confirmed 
COVID-19 infection, OSA should be recognised as one 
of the comorbidity risk factors for developing a severe 
form of the disease. We believe that our finding may help 
in identifying high- risk individuals for severe forms of 
COVID-19 infection and therefore screening for previous 
indications of OSA could be beneficial among individ-
uals testing positive for the virus.
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